Pune: Emcure Pharmaceuticals Ltd has entered into a distribution agreement with Roche to expand patient access to critical therapies in nephrology and transplant care across India.
The partnership, effective April 1, 2026, will see Emcure distribute Roche’s established nephrology and transplant portfolio in the country.
The distribution agreement between Emcure Pharmaceuticals and Roche marks a significant step toward strengthening nephrology and transplant care in India, particularly in chronic kidney disease (CKD), anemia management, and post-transplant treatment.
Under the agreement, Emcure Pharmaceuticals will distribute Roche’s globally recognised brands in the nephrology and transplant segment through its extensive distribution and clinical network.
Also Read: India Delaware Biomanufacturing Working Group to Drive Startup, R&D and Supply Chain Cooperation
Portfolio to Include CellCept, Mircera and NeoRecormon
As part of the Emcure Pharmaceuticals Roche distribution agreement, the portfolio will include:
- CellCept – A globally leading immunosuppressant and original Roche innovation, supporting organ transplants worldwide since 1995.
- Mircera and NeoRecormon – Proven therapies for anemia in chronic kidney disease, including Mircera’s long-acting ESA with dosing once every 2–4 weeks.
Through this collaboration, Emcure Pharmaceuticals will distribute Roche’s nephrology and transplant brands to a wider cross-section of patients across India, enhancing access to critical medicines for CKD patients and transplant recipients.
Strategic Alignment in Nephrology and Anemia Management
Emcure Pharmaceuticals is a market leader in anemia management and, together with its subsidiaries, has a strong presence across nephrology and chronic kidney disease segments.
Roche’s nephrology and transplant portfolio complements Emcure’s existing offerings, enabling the company to strengthen its therapeutic presence in renal care and transplant medicine.
Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals, said, “This partnership with Roche is a natural extension of Emcure’s commitment to improving outcomes in anemia and renal care. Roche’s globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering optimal care to patients across India.”
Rajji Mehdwan, Managing Director & CEO, Roche India & Neighbouring Markets, added, “We are pleased to partner with Emcure Pharmaceuticals, a company with deep expertise and leadership in anemia management and nephrology. Through Emcure’s strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients who can benefit from Roche’s long-standing innovations in transplant and CKD care.”
Also Read: Potpie AI Announces $2.2 Million Round Led by Emergent Ventures
The agreement is aimed at improving patient access to proven therapies while supporting better anemia management and long-term outcomes for patients with chronic kidney disease and transplant needs.
Growing Need for CKD and Transplant Therapies in India
With the rising burden of chronic kidney disease and increasing transplant care requirements in India, the distribution agreement highlights collaboration between global innovators and Indian pharmaceutical companies to improve access to specialised therapies.
Effective April 1, 2026, Emcure Pharmaceuticals will leverage its distribution capabilities and clinical engagement to ensure that Roche’s nephrology and transplant therapies reach patients across the country.
